F S&P 500
5,308.00 +12.50 (+0.24%) F Dow Jones
38,797.00 +6.00 (+0.02%) F Nasdaq
18,693.25 +102.25 (+0.55%) E-mini Russell 2000 Index Futur
2,101.30 +25.50 (+1.23%) Petróleo
77.11 +0.12 (+0.16%) Oro
2,346.60 +0.80 (+0.03%)
Tango Therapeutics, Inc. (TNGX)
Fuera de horario:
Tango Therapeutics, Inc.
201 Brookline Avenue
Suite 901
Boston, MA 02215
United States
857 320 4900
https://www.tangotx.com
Sector(es): Healthcare
Industria: Biotechnology
Empleados a tiempo completo: 140
Ejecutivos clave
| Nombre | Título | Pagar | Ejecutado | Año de nacimiento |
|---|---|---|---|---|
| Dr. Barbara L. Weber M.D. | President, CEO & Director | 1.04M | N/D | 1957 |
| Dr. Adam S. Crystal M.D., Ph.D. | President of Research & Development | 977.22k | N/D | 1977 |
| Dr. Alan Ashworth FRS, Ph.D. | Founder & Member of Scientific Advisory Board | N/D | N/D | 1961 |
| Dr. Levi Garraway M.D., Ph.D. | Founder | N/D | N/D | 1969 |
| Dr. William G. Kaelin Jr., M.D. | Founder & Member of Scientific Advisory Board | N/D | N/D | 1958 |
| Dr. Timothy K. Lu M.D., Ph.D. | Founder | N/D | N/D | 1981 |
| Dr. Antoni Ribas M.D., Ph.D. | Founder & Member of Scientific Advisory Board | N/D | N/D | 1967 |
| Mr. Timothy Redfern | Chief Financial Officer | N/D | N/D | 1979 |
| Mr. Jannik N. Andersen Ph.D. | Chief Scientific Officer | N/D | N/D | N/D |
| Mr. Douglas J. Barry Esq., J.D. | Chief Legal Officer, Chief Compliance Officer & Corporate Secretary | N/D | N/D | 1970 |
Descripción
Tango Therapeutics, Inc., a biotechnology company, discovers and develops drugs for the treatment of cancer. Its lead program is TNG908, a synthetic lethal small molecule inhibitor of protein arginine methyltransferase 5 that is being developed as a treatment for cancers with methylthioadenosine phosphorylase deletions. The company develops TNG462, an oral small molecule methylthioadenosine-cooperative inhibitor for the treatment for cancers with methylthioadenosine phosphorylase deletions; TNG260, a co-repressor of repressor element-1 silencing transcription -selective inhibitor; TNG348, an ubiquitin-specific protease 1 inhibitor to treat patients with BRCA1 or BRCA2-mutant cancers; and Target 3 for STK11-mutant cancers. It has a strategic collaboration with Gilead Sciences, Inc. for the discovery, development, and commercialization of a pipeline of therapies for patients with cancer. Tango Therapeutics, Inc. was founded in 2017 and is headquartered in Boston, Massachusetts.
Gestión corporativa
La calificación ISS Governance QuickScore de Tango Therapeutics, Inc. a partir del 1 de junio de 2024 es 7. Las puntuaciones principales son Auditoría: 8; Junta: 4; Derechos del accionista: 8; Compensación: 9.
